Azficel-T
Alternative Names: Autologous human fibroblasts - Fibrocell Science; Azfibrocel-T; azficel-T fibroblast suspension; Fibroblast cell therapy - Fibrocell Science; Isolagen therapy; LavivLatest Information Update: 19 Dec 2019
At a glance
- Originator Isolagen
- Developer Fibrocell Science
- Class Cell therapies; Fibroblast cell therapies; Skin disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Dysphonia; Periodontal disorders; Scars
Highest Development Phases
- Marketed Facial wrinkles
- Discontinued Dysphonia; Periodontal disorders; Scars
Most Recent Events
- 16 Dec 2019 Fibrocell Science has been acquired by Castle Creek Pharmaceuticals
- 21 Dec 2016 Fibrocell Science completes a phase II trial for Dysphonia in USA (Injection) (NCT02120781)
- 07 Jul 2016 Fibrocell Technologies terminates phase II trial in Scars (Restrictive burn scars) in USA (NCT01858753)